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Purpose: Olive oil, being rich in mono-unsaturated fatty acids and anti-inflammatory 
compounds, may have protective effects against cardiovascular disease (CVD). The 
aim of the present work was to examine the association of olive oil consumption with 
the 10-year CVD incidence in adults without pre-existing CVD. Methods: The 
ATTICA Study is a prospective, population-based study conducted in the greater 
metropolitan area of Athens (Attica, Greece). During 2001-2002, 3042 CVD-free 
adults (1514 men and 1528 women) were voluntarily recruited to the ATTICA study. 
Among various dietary habits, consumption of olive oil and other fats/oils was 
assessed at baseline; participants were classified into three groups (no use; mixed use; 
and exclusive use of olive oil). In 2011-2012, the 10-year study follow-up was 
performed, recording the fatal/non-fatal CVD incidence in 2020 participants (mean 
follow-up duration: 8.41 years). Results: After controlling for various covariates, an 
inverse association between exclusive olive oil use and the risk of developing CVD 
was observed (relative risk 0.07, 95%CI: 0.01-0.66) compared to those not consuming 
olive oil. Further adjustment for fibrinogen plasma levels (among various 
inflammatory markers) showed a significant mediation effect on the previous 
association. Conclusions: These findings support exclusive olive oil consumption, a 
key component of the Mediterranean diet, for the primary CVD prevention, in adults 
without pre-existing disease. Circulating fibrinogen levels appear to play a mediating 
role in this relationship.  
Keywords: olive oil, cardiovascular disease, nutrition, inflammation, fibrinogen 
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1. Introduction 
Non-communicable diseases account for 70% of all deaths globally, with 
cardiovascular disease (CVD) constituting the most common cause (3.9 million CVD-
related deaths in Europe, accounting for 45% of all deaths) [1]. Notably, mortality 
rates from ischaemic heart disease and stroke tend to be generally higher in Central 
and Eastern Europe than in Western and Southern Europe (e.g. in France, Spain, 
Greece, Italy and Portugal) [1, 2], contributing to the trends for longer life expectancy 
in these countries. Among the behavioral CVD risk factors, dietary factors are 
considered to have the greatest impact on CVD mortality/morbidity [1]. Indeed, the 
Mediterranean diet has been proposed as one of the major protective factors 
responsible for these geographical disparities in CVD mortality trends [3, 4]. 
The typical Mediterranean diet represents the traditional dietary pattern that 
prevailed in olive-growing areas of the Mediterranean region, such as the Greek 
island of Crete and southern Italy, in the late 1950s and early 1960s [5]. As such, 
olive oil, being the main source of culinary fat in these countries/regions [6, 7], is 
regarded as a key component of the traditional Mediterranean diet. In recent years, 
several health benefits have been credited to olive oil (virgin or refined) consumption 
and its nutritional value [8]. These are mainly attributed to its high content of mono-
unsaturated fatty acids (MUFA), antioxidants and anti-inflammatory compounds, 
which may exert beneficial effects against the development and progression of 
diseases associated with chronic low-grade inflammation, including CVD where 
chronic inflammation of the vascular endothelium is linked to CVD events [8].     
 Compiling epidemiological data suggest that olive oil intake is inversely 
associated with CVD [9-12]. In the Spanish branch of the European Prospective 
Investigation into Cancer and Nutrition (EPIC) study, the total olive oil intake was 
associated with decreased risk of coronary heart disease (CHD) and lower all-cause 
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and CVD mortality [10]. Similarly, the Prevention through Mediterranean Diet 
(PREDIMED) randomized clinical trial showed that a Mediterranean diet 
supplemented with olive oil reduces the incidence of CVD episodes and mortality in 
high CVD risk patients [11]. Moreover, in a case-control study conducted in Greece 
exclusive use of olive oil was also found to have a significant protective effect against 
acute coronary syndromes [12]. 
Despite the increasing evidence supporting the protective effects of olive oil 
consumption in relation to CVD and chronic subclinical inflammation [8], limited 
epidemiological data exist from the general population on the relationship between 
olive oil intake and long-term CVD risk. Therefore, the aim of the current work was 
to prospectively examine the association of olive oil consumption with the 10-year 
CVD incidence in the ATTICA study cohort of adults without pre-existing CVD. 
  
2. Materials and Methods 
2.1 Sampling procedure at baseline  
The ATTICA Study is a prospective, population-based study conducted in the 
greater metropolitan area of Athens (Attica region, Greece). The study baseline 
examination was performed during 2001-2002, as previously described [13]. Briefly, 
the study was designed to enroll only one participant per household through a 
random, multistage process based on the age/sex distribution of the general 
population of the Attica region (2001 National Census). A total of 3042 free-living, 
Caucasian adults [1514 men (age: 18-87 years); 1528 women (age: 18-89 years)] 
consented to participate and were assessed by trained personnel, as per study protocol 
[13]. The study’s physicians performed exclusion of individuals with pre-existing 
CVD at baseline through a detailed clinical evaluation. 
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2.2 Baseline measurements 
The baseline evaluation included data on demographic characteristics (e.g., 
age, sex, education), personal/family medical history (e.g. hypercholesterolemia, 
hypertension and diabetes), as well as dietary and other lifestyle habits (e.g. smoking 
status and physical activity) [13]. In the context of the present study, smokers were 
defined as those who smoked at least one cigarette per day or had stopped smoking 
during the preceding year (the rest of the participants were defined as non-smokers), 
and education was measured in years of school. Dietary habits were assessed based on 
a validated semi-quantitative food-frequency questionnaire (FFQ) [14], namely the 
EPIC-Greek questionnaire, which was kindly provided by the Unit of Nutrition of 
Athens Medical School. Moreover, the MedDietScore was also applied to assess the 
adherence to the Mediterranean diet (range 0-55; higher score values indicating 
greater adherence to the Mediterranean diet), as previously described [15]. In 
addition, study participants were asked to report the average intake of several foods 
and liquids consumed during the previous 12 months, and data on the total energy 
intake (kcal/day), ethanol intake (g/d), and percent (%) energy intake from fat were 
calculated based on food composition tables. Moreover, the intake of MUFA, 
saturated fatty acids (SFA), and trans-fatty acids (TFA), as well as the MUFA/SFA 
intake ratio and omega-3 fatty acids, were also calculated based on the information 
retrieved through the FFQ and relevant food composition tables. To evaluate the 
baseline physical activity status of study participants the International Physical 
Activity Questionnaire was used (IPAQ) [16], as an index of weekly energy 
expenditure using frequency (times per week), duration (in minutes per time) and 
intensity of sports or other habits related to physical activity (in expended calories per 
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time). Accordingly, participants who did not report any physical activities were 
defined as physically inactive.  
Anthropometric measurements were performed for all participants at baseline 
and the body mass index (BMI) was calculated as weight (in Kg) divided by standing 
height (in square meters, m2). The waist-to-hip ratio (WHR) was also calculated for 
each participant based on the hip and waist circumference measured (to the nearest 
0.5 cm) using an inelastic measuring tape at the iliac crest and in the middle between 
the lowest rib and the iliac crest, respectively.  
Arterial blood pressure (mean of 3 recordings) was also measured at the end of 
the baseline physical examination with the study participant in a sitting position after 
resting for at least 30 minutes. Participants with average blood pressure levels greater 
or equal to 140/90 mmHg (or on antihypertensive treatment) were classified as having 
hypertension.  
Baseline blood samples were also collected from each participant at 8-10 am 
after 10-12 hours of overnight fasting and alcohol abstinence. From these samples, 
blood lipids (total cholesterol, HDL-cholesterol and triglycerides) were measured 
using a chromatographic enzymic method in a Technicon automatic analyser RA-
1000 (Dade Behring, Marburg, Germany). Hypercholesterolemia was defined as total 
cholesterol levels greater than 200 mg/dl (or treatment with lipid-lowering agents). 
Blood glucose levels (mg/dl) were measured with a Beckman Glucose Analyzer 
(Beckman Instruments, Fullerton, CA, USA), and participants with fasting blood 
glucose levels greater than 125 mg/dl were classified as having diabetes according to 
the American Diabetes Association diagnostic criteria [17]. In addition, measurements 
of selected circulating pro-inflammatory biomarkers were also performed, including 
C-reactive protein (CRP), fibrinogen, and interleukin-6 (IL-6), as well as 
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homocysteine and plasma oxidized LDL-cholesterol (ox-LDL; as an oxidative stress 
biomarker). High sensitivity CRP was assayed by particle-enhanced 
immunonephelometry (N Latex, Dade-Behring Marburg GmbH, Marburg, Germany) 
and participants with CRP levels above 10 mg/L were excluded from the analyses.  
In the context of this work, the participants were also classified according to 
the presence/absence of metabolic syndrome (MetS), using the criteria of the NCEP 
ATP III (revised 2005) MetS definition [18].  
2.3 Olive oil consumption at baseline 
All participants provided detailed information on the consumption of olive oil, 
vegetable seed oils, butter and margarines by reporting the use of various oils in daily 
cooking and preparation of meals (e.g. addition to salads, dressings, etc.). Based on 
the reported baseline olive oil consumption, study participants were divided to those 
reporting daily olive oil use/consumption and those reporting no olive oil intake at all, 
and were also further sub-grouped into three categories, namely to no olive oil use 
group (consumption of other dietary fats/oils except for olive oil), mixed use group 
(combined use of olive oil and other dietary fats/oils) and exclusive olive oil use 
group (consumption/use of olive oil only). 
2.4 Follow-up examination (2011-2012) 
During 2011-12, the 10-year follow-up of the ATTICA Study was performed 
by trained study investigators (mean follow-up duration: 8.41 years), as previously 
described [19]. In brief, 2583 of the 3042 initially enrolled participants were re-
evaluated for this follow-up [85% participation rate; mean age at baseline (years ± 
standard deviation): 45±14 and 46±14 years for women and men, respectively, with 
no difference to the overall study sample]. Detailed evaluation of the medical records 
of all these re-evaluated participants (n=2583) was performed, focusing on their 10-
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year CVD status, and data (with WHO-ICD coding) were collected for: (a) vital status 
(death from any cause or due to CVD); (b) development of CVD, including 
myocardial infarction, angina pectoris, other identified forms of ischemia, heart 
failure of different types, chronic arrhythmias and stroke [19]. Regarding the CVD 
status at the 10-year follow-up, clinically accurate and complete data were obtained 
from 2020 study participants (Table 1). For the aims of the present study in order to 
explore the association of olive oil consumption with long-term CVD risk, herein we 
present our data in relation to the 10-year incidence of fatal/non-fatal CVD for these 
2020 study participants. 
2.5 Bioethics 
The study was approved by the Bioethics Committee of Athens Medical 
School and was carried out in accordance to the Declaration of Helsinki (1989) of the 
World Medical Association. Prior to any study-related procedures, each participant 
was informed on the aims and protocol of the study and provided written signed 
consent. 
2.6 Statistical analysis 
Crude, non-fatal and fatal incidence rates of combined CVD (i.e., coronary 
heart disease or stroke) were calculated as the ratio of new cases to the number of 
study participants in the 10-year follow-up. Continuous variables were tested for 
normality through P-P plots and are presented as mean values ± standard deviation 
(SD) or as median if not normally distributed, whilst categorical variables are 
presented as frequencies. Associations between categorical variables were tested 
using the chi-square test, while between continuous variables using the Pearson r or 
Spearman’s rho coefficients for the normally and skewed variables, respectively. 
Comparisons of mean values of normally distributed variables by olive oil 
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use/consumption were performed using analysis of variance (ANOVA), and post-hoc 
analyses using the Bonferroni rule were performed to account for the inflation of the 
probability of type-I error. Comparisons between mean values of normally distributed 
variables between those who developed a CVD event and the rest of the participants 
who remained CVD-free were performed using Student’s t-test, after controlling for 
equality of variances using the Levene’s test. Comparisons of continuous variables 
that did not follow a normal distribution were performed using the non-parametric U-
test proposed by Mann and Whitney and the Kruskal-Wallis H-test. The hazard ratios 
(HR) and the corresponding 95% confidence intervals (CI) of developing a CVD 
event during the 10-year period according to the participants’ baseline characteristics 
were estimated using Cox proportional hazards models. The time to CVD event was 
recorded on an annual basis. Multicolinearity between independent variables was 
tested using the Correlation Matrix of the models’ estimates. Sobel’s test was applied 
to test for a potential mediating effect of various biomarkers on the tested association. 
All reported p-values are based on two-sided tests. The Statistical Package for Social 




3.1 Baseline characteristics of study participants by olive oil consumption status 
Based on the baseline dietary reports, 89.5% of the 2020 participants reported 
daily olive oil consumption (mixed with other additive fats or exclusive, while the rest 
(10.5%) reported no olive oil use/consumption; particularly, exclusive olive oil use in 
daily cooking was reported by 1.1% of the participants. Table 1 presents the 
demographic, clinical, lifestyle and behavioral characteristics of these study 
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participants based on olive oil consumption at baseline (no use vs. daily use). Overall, 
compared to participants reporting no olive oil use, those who reported daily olive oil 
consumption at baseline were younger, less likely to be smokers, and had lower BMI 
values; but had higher WHR and waist circumference, higher fasting levels of plasma 
lipids and were also more likely to have MetS at baseline (Table 1; all p-values 
<0.05). Participants who consumed olive oil on a daily basis exhibited closer 
adherence to the Mediterranean diet, as indicated by the higher MedDietScore 
(p=0.03), and a higher MUFA/SFA ratio intake (p=0.006), whilst they also had lower 
energy intake from SFA (p=0.007) compared to participants reporting no olive oil use 
(Table 1). As far as omega-3 intake is concerned, participants reporting olive oil use 
on a daily basis had higher levels of omega-3 fatty (g/d) acids compared to olive oil 
abstainers (mean ± SD: 2.19±0.80 vs. 2.11±0.59, p-value=0.002). 
3.2 10-year CVD incidence and baseline olive oil consumption 
The 10-year fatal or non-fatal CVD event rate documented in the study was 
157 cases/1000 participants [i.e., n=317 subjects; men: n=198 (195 cases/1000 
participants); women: n=119 (118 cases/1000 participants); p for gender difference 
<0.001].  
A significant association was observed when compared participants with no 
olive use with those reported (mixed or exclusive) use as regards 10-year CVD risk 
(Table 1). Moreover, after classifying the participants into three groups, i.e. no olive 
oil use group, mixed use group and exclusive olive oil use, participants in the no olive 
oil use or in the mixed use group (i.e., consuming olive oil along with other dietary 
fats/oils) were 4.2-times and 5.3-times more likely to develop a CVD event during the 
10-year study follow-up compared to those reporting exclusive olive oil use. 
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The aforementioned comparisons may be prone to residual confounding due to 
various factors. Thus, multi-adjusted analysis was also performed, controlling for 
multiple CVD-related covariates (Table 2). Age-sex analysis revealed a significant 
protective association between exclusive olive oil consumption and the 10-year CVD 
incidence (Table 2, Model 1); even when other variables (i.e., BMI, smoking, 
physical activity status, education, hypertension, diabetes, hypercholesterolemia, and 
MetS) were entered in this model as potential confounders or mediating factors, 
participants who consumed exclusively olive oil at baseline had a 93% lower risk of a 
CVD event during the study follow-up period compared to the no olive oil use group 
(Table 2, Model 2). Similarly, when MedDietScore and omega-3 fatty acids intake 
were entered in the model, the effect size of the association between olive oil use and 
CVD risk remained unaltered (data not shown). Moreover, no significant interactions 
were observed between olive oil use and the aforementioned potential confounders / 
mediating factors. 
Taking into account that sub-clinical, low-grade inflammation could be a 
possible mediator of the association between exclusive olive oil consumption and the 
CVD risk, selected relevant circulating biomarkers were entered, consecutively (and 
separately) in the fully adjusted model (Model 2). Amongst these tested models, only 
adjustment for fibrinogen plasma levels showed a significant mediation of olive oil 
use on CVD risk (Model 3, Table 2; p for Sobel’s test 0.05). Contrary, the models 
including CRP, ox-LDL, IL-6 and homocysteine, did not alter the impact of olive oil 
use on CVD risk (OR=1.05, 95% CI: 0.98-1.12; OR=1.00, 95% CI: 0.99-1.01; 
OR=1.02, 95% CI: 0.78-1.34; OR=1.01, 95% CI: 0.97-1.03, respectively) 




 The present study reported novel data from a large cohort of prospectively 
followed adults without pre-existing CVD, showing a significant inverse association 
between exclusive use/consumption of olive oil and the 10-year CVD incidence, 
irrespective of the level of adherence to the Mediterranean diet and or other important 
constituents (e.g., omega-3 fatty acids intake). Of note, the reported results further 
suggest that fibrinogen, which is a key plasma coagulation factor with a potential pro-
inflammatory role in vascular wall disease [20], may have a mediating effect in this 
protective association. Interestingly, there is evidence in the literature indicating that 
olive oil consumption can lower plasma fibrinogen levels and impact on platelet 
function, thrombogenesis and fibrinolysis [21, 22]. The fact that fibrinogen levels 
may better reflect vascular damage, could, partially be an explanation of the present 
study’s findings, regarding the lack of mediating effect from the other inflammatory 
markers levels. However, the link between olive oil consumption, haemostasis, 
subclinical inflammation and CVD offers an intriguing hypothesis, which requires 
further experimental research. The presented findings are of particular importance for 
public health strategies on nutrition/diet and primary CVD prevention, supporting the 
notion that olive oil may be a key-player for the protection against CVD in the general 
population, potentially involving haemostasis and pro-inflammatory mechanisms. 
The beneficial effects of olive oil are mainly attributed to its high content of 
MUFA (i.e., mainly to oleic acid), although other minor compounds/components, 
such as lipid molecules (e.g., squalene, tocopherols, triterpernic alcohols) and phenols 
(e.g., hydroxytyrosol and oleuropein) may also have important biological properties. 
This has particular importance, as recent studies have showed that hydroxytyrosol 
helps to improve plasma lipids levels and repair oxidative damage related to CVD [8, 
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22]. Moreover, in a recent study located in southern Spain a greater dietary 
consumption of polyphenols in olive oil among participants who more closely 
followed the Mediterranean diet pattern, was observed; a fact that may also explain 
the cardioprotective effects of olive oil [23]. Of note, its high MUFA content confers 
to olive oil (virgin or refined) high resistance to elevated temperatures, thus allowing 
it to be reutilized more than once for frying [24]. In comparison to SFA from butter 
and margarine, olive oil/MUFA reduces low-density lipoprotein cholesterol (LDL) 
and favors an increase in high-density lipoprotein cholesterol (HDL) levels [8]. 
Furthermore, taking into consideration that the phenolic compounds of olive oil are 
potential scavengers of superoxide radicals and inhibit LDL oxidation, the effect of 
olive oil consumption on preserving the endothelial function may offer an additional 
benefit against the links between endothelial dysfunction, oxidative stress, 
inflammation and CVD [25, 26]. Moreover, a recent meta-analysis of randomized 
controlled trials (RCTs) investigating the effects of olive oil on markers of 
inflammation and endothelial function suggested that both pro-inflammatory 
biomarkers (CRP and IL-6) and endothelial function (flow-mediated dilatation) were 
favorably affected following interventions with olive oil [27]. It becomes evident, that 
all these mechanisms support the advantages of exclusive olive oil consumption 
compared to SFA-rich dietary patterns (e.g. cooking with butter and margarine) and 
may explain its protective role against CVD [8, 23]. 
It is also important to note the present findings are in accord with the existing 
epidemiological evidence from prospective studies showing that high olive oil 
consumption is inversely associated with CVD risk [10, 28, 29]. Indeed, in the 
EPICOR study reduced CVD risk (HR=0.56; 95%CI: 0.31-0.99) was observed among 
Italian women in the highest quartile of olive oil consumption during the study 
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follow-up period (approximately 8 years) [28]. Moreover, in the EPIC-Spain study 
(13.4 years of follow-up) participants in the highest quartile of olive oil consumption 
had a 44% lower risk in CVD mortality compared to those not consuming olive oil 
[10]. The beneficial impact of olive oil consumption against CVD was further 
supported by the PREDIMED study, which showed that a Mediterranean diet 
supplemented with extra-virgin oil was associated with a clear reduction in CVD 
events (HR=0.70; 95%CI: 0.54-0.92) in individuals at high CVD risk [29]. As such, 
the results presented are in agreement with the results of the PREDIMED study that 
highlighted olive oil consumption as a crucial Mediterranean Diet component for 
CVD prevention [11, 29]. It is of interest that the observed findings were not altered 
by the dietary pattern that the ATTICA study participants followed. Specifically, 
although olive oil consumers were higher adherers to the traditional dietary pattern 
and also reported higher omega-3 fatty acids intake, when adherence to the 
Mediterranean diet was taken into account in the epidemiological models, no 
alterations were observed in the tested relationship between olive oil and CVD risk, 
enhancing the important role of olive oil on the cardiovascular system.    
Taking into consideration the traditional dietary patterns in Europe, it is not 
surprising that most of the limited existing prospective studies on the association 
between exclusive olive oil use and CVD risk are from Greece [12, 30, 31]. Although 
these previous studies focused on patients with coronary artery disease, their results 
also agree with the findings of the present study [12, 30, 31]. Indeed, the Greek 
CARDIO2000 case-control study, examined the association between exclusive olive 
oil consumption and the risk of developing acute coronary syndromes (ACS) in a 
large sample of ACS patients and CVD-free controls (748 cases and 1048 controls) 
showing a protective effect for the exclusive olive oil use against ACS (OR=0.53, 
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95% CI: 0.34-0.71) [12]. Moreover, the prospective GREECS study for secondary 
CVD prevention among patients with a history of ACS, exhibited an association 
between exclusive olive oil consumption and lower risk of recurrent ACS events [31].   
4.1 Study strengths and limitations  
The data of this work were obtained through a reliable and prospective follow-
up process in a well-characterized, large CVD-free cohort from the general population 
in which multiple CVD-associated risk factors were comprehensively assessed with 
standardized procedures/methods. The characteristics of the study design/protocol and 
population strengthen the significance of the findings, since the associations of the 
olive oil consumption pattern with long-term CVD-risk were explored at baseline in a 
unique cohort from a Mediterranean country that traditionally has the highest daily 
use of olive oil in food cooking/preparation, while adjusting for multiple confounders.   
However, certain study limitations must be also acknowledged. As such, it 
should be noted that the baseline study examination was performed once, hence may 
be susceptible to measurement error. Furthermore, the daily quantity of olive oil 
consumption was not evaluated, and therefore, it was not able to provide information 
about the contribution of olive oil to the total fat intake, as well as fat from ready to 
eat meals. Moreover, there was no characterization of the different varieties of olive 
oil (e.g. common, virgin or extra virgin olive oil), and, thus, the role of polyphenol 
intake was not specifically explored in this context. Moreover, it is possible that a 
number of participants may have changed their olive oil use habits during the follow-
up period. Nevertheless, the applied methodology is similar to that followed in other 
prospective epidemiological studies in this field and, thus, the results can be 
considered reliable and generally comparable.  
4.2 Conclusions 
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The present study offers evidence revealing an independent inverse 
association between exclusive olive oil use/consumption and CVD incidence in a 
cohort of Caucasian/Mediterranean adults without previous CVD. In addition, the  
multi-adjusted analyses suggest that fibrinogen may play a mediating role in this 
protective association. As such, these findings from the ATTICA study cohort extend 
the existing epidemiological evidence in this field and highlight the beneficial impact 
of olive oil consumption, a key component of the Mediterranean diet, on primary 
CVD prevention.  
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Table 1. Selected characteristics (demographic, lifestyle, clinical and diet characteristics) of the ATTICA 





Olive oil use/consumption P 
No use 
n=212 (10.5%) 




10-year CVD events, % 15.7 12.8 3.0 0.03 
Age (years) 45 ± 14 50 ± 15 44 ± 14 <0.001 
Gender, %male 50 48 50 0.39 
Smoking habits, %yes 43 50 43 0.012 
Physical Activity, %physically active 41 39 40 0.46 
Body Mass Index (kg/m2) 26 ± 5 27 ± 4 26 ± 5 0.04 
Waist circumference (cm) 90 ± 15 88 ± 16 90 ± 14 0.03 
Waist-to-hip ratio 0.86 ± 0.1 0.83 ± 0.09 0.86 ± 0.11 <0.001 
Education (years of school) 12 ± 4 11 ± 3 12 ± 4 <0.001 
Hypertension, %yes 30 27 30 0.29 
Diabetes Mellitus, %yes 7  8 7 0.49 
Hypercholesterolemia, %yes 39 26 41 <0.001 
Metabolic syndrome, %yes 20 10 21 <0.001 
Fibrinogen (mg/dL) 311± 69 309 ± 66 311 ± 70 0.69 
Baseline dietary factors 
MedDietScore (range 0-55) 26 ± 7 25 ± 8 27 ± 7 0.03 
Total energy intake (kcal/day) 2365 ± 952 2292 ± 963 2371± 951 0.44 
Ethanol intake (g/d) 15 ± 15 14 ± 11 16 ± 17 0.21 
Energy intake from fat, % 35 34 35 0.89 
Energy intake from SFA, % 10 10 9 0.007 
Energy intake from MUFA, % 23 23 24 0.37 
MUFA/SFA intake ratio intake 1.7 ± 0.49 1.6 ± 0.48 1.8 ± 0.47 0.006 
Energy from trans-fatty acids, % 0.59 0.60 0.59 0.90 
1 Hazard Ratios derived from semiparametric Cox proportional hazards models.  
2 p-value <0.05 
 
Table 2. Results from the Cox proportional hazards models [Hazard Ratios (HR) and 95% confidence intervals 
(CI)] that were applied to evaluate the 10-year risk of developing a fatal or non-fatal cardiovascular disease 
(CVD) event (outcome) according to the olive oil use/consumption pattern at baseline. 
 Hazard Ratios1, 95% Confidence Intervals 
 Model 1 Model 2 Model 3 
Olive oil use       
No use (reference category) 1.00 - 1.00 - 1.00 - 
Mixed use with other oils/fats in cooking 0.98 0.52, 1.852 0.91 0.45, 1.832 2.02 0.69-5.902 
Exclusive use in daily cooking 0.11 0.01, 0.952 0.07 0.01-0.662 0.24 0.02-2.542 
Age (per 1 year) 1.09 1.08, 1.10 1.08 1.07-1.10 1.07 1.06-1.09 
Men vs. Women 1.99 1.52, 2.63 1.72  1.28-2.33 1.78 1.27-2.50 
Body Mass Index (per 1 kg/m2) - - 1.03 0.99-1.07 1.03 0.99-1.07 
Smoking habits (ever vs. never) - - 1.30 0.96-1.78 1.44 1.02-2.05 
Physically active vs. inactive - - 0.97  0.72-1.30 0.98 0.70-1.37 
Education (>14 years vs. <9 years) - - 0.97 0.93-1.01 0.96 0.92-1.00 
History of        
Hypertension (y/n) - - 1.04 0.77-1.42 1.01 0.71-1.43 
Hypercholesterolemia (y/n) - - 1.07 0.80-1.43 1.11 0.80-1.54 
Diabetes mellitus (y/n)   1.67 1.08-2.59 1.47 0.89-2.44 
Metabolic syndrome (y/n) - - 1.56 1.12-2.20 1.76 1.19-2.60 
Fibrinogen (per 1 mg/dL)     1.00 1.00-1.01 
